Talks
The Next Five Years in Myeloma
October 5, 2026
The Future of MRD-Guided Therapy
October 5, 2026
The Future of In-Vivo CAR-T
October 5, 2026
The Value of Deep Responses
October 5, 2026
Key Takeaways From IMS 2026
October 5, 2026
Immunotherapy Moves Earlier
October 5, 2026
The Role of Mezigdomide
October 5, 2026
Redefining Myeloma Treatment
October 5, 2026
Genomics and Myeloma Risk
October 5, 2026
The Evolution of Myeloma
October 5, 2026
Close button
Why are you reporting this TALK?